DBV Technologies Announces Appointment of Virginie Boucinha as Chief Financial Officer
October 16 2023 - 1:00AM
Montrouge, France, October 16, 2023
DBV Technologies Announces Appointment
of Virginie Boucinha as Chief Financial Officer
DBV Technologies (Euronext: DBV – ISIN:
FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage
biopharmaceutical company, today announced the appointment of
Virginie Boucinha as its Chief Financial Officer, effective
November 6, 2023. An experienced financial and operations
executive, Virginie will report directly to Daniel Tassé, Chief
Executive Officer, and serve as a member of the Executive
Committee.
“I am pleased to welcome Virginie to the DBV
Executive Committee to lead our global financial organization,”
said Daniel Tassé, Chief Executive Officer, DBV Technologies.
“Virginie is collaborative, results-focused, and brings extensive
experience in finance, strategy, and global management across the
pharmaceutical industry. I know she will bring great value to our
leadership team.”
Virginie will be responsible for DBV’s financial
management and operations, information technology, strategic
planning, and investor relations. Virginie brings approximately 30
years of diverse experience in the pharmaceutical industry. She
most recently served as the Group Performance Director for Pierre
Fabre. Prior to this, Virginie held various senior positions at
Sanofi, including Chief of Staff to the Sanofi CEO, Global
Transformation Office Head, and Chief Financial Officer for India
and South Asia. She is trained in finance as a graduate of Ecole
Superieure de Gestion where she obtained a Master of Business
Administration. Virginie will be based at DBV’s headquarters in
Montrouge, France.
“I am thrilled to be joining DBV Technologies at
such a critical juncture,” said Ms. Boucinha. “The Company is
swiftly advancing two, distinct BLAs for Viaskin in toddlers and
children living with a peanut allergy. It is imperative that DBV
maintains the same financial discipline that our shareholders have
come to expect, while wisely positioning the Company for regulatory
and commercial success. I am looking forward to this mission and to
collaborating alongside the broader DBV Executive team.”
Sébastien Robitaille, Chief Financial Officer,
DBV Technologies, will be leaving the Company to pursue other
opportunities on November 17th. Virginie will
onboard on November 6, 2023, allowing for a smooth two-week
transition between executives.
“I am thankful to Sébastien for his many
contributions to DBV over the years,” said Mr. Tassé. “We are
fortunate to have had his guidance on the Executive Committee. As
DBV’s Chief Financial Officer, Sébastien helped facilitate our
corporate restructuring and upheld financial discipline. We are a
more agile and flexible organization thanks to his work. I wish him
the very best in his next endeavors.”
Sébastien Robitaille joined DBV in 2015 and was
appointed as Chief Financial Officer in 2020.
“It has been a privilege to work alongside
colleagues that are dedicated and passionate about making a
difference in the lives of others,” said Sébastien Robitaille,
Chief Financial Officer, DBV Technologies. ”I remain steadfast in
my belief that DBV will one day provide treatment options for those
living with food allergies through the Viaskin platform.”
About DBV TechnologiesDBV
Technologies is developing Viaskin™, an investigational proprietary
technology platform with broad potential applications in
immunotherapy. Viaskin is based on epicutaneous immunotherapy, or
EPIT™, and is DBV Technologies’ method of delivering biologically
active compounds to the immune system through intact skin. With
this new class of non-invasive product candidates, the Company is
dedicated to safely transforming the care of food allergic
patients. DBV Technologies’ food allergies programs include ongoing
clinical trials of Viaskin Peanut. DBV Technologies has global
headquarters in Montrouge, France, and North American operations in
Basking Ridge, NJ. The Company’s ordinary shares are traded on
segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345)
and the Company’s ADSs (each representing one-half of one ordinary
share) are traded on the Nasdaq Global Select Market (Ticker:
DBVT).
Forward Looking StatementThis
press release may contain forward-looking statements and estimates,
including, but not limited to, statements regarding the therapeutic
potential of Viaskin™ Peanut and EPIT™ and DBV’s Technologies’
planned regulatory and clinical efforts, financial strategy, and
leadership changes These forward-looking statements and estimates
are not promises or guarantees and involve substantial risks and
uncertainties and may be impacted by market conditions as well as
other risks and uncertainties set forth in DBV Technologies’
regulatory filings with the Autorité des Marchés Financiers
(“AMF”), DBV Technologies’ filings and reports with the U.S.
Securities and Exchange Commission (“SEC”), and future filings and
reports made with the AMF and SEC. Existing and prospective
investors are cautioned not to place undue reliance on these
forward-looking statements and estimates, which speak only as of
the date hereof. Other than as required by applicable law, DBV
Technologies undertakes no obligation to update or revise the
information contained in this Press Release.
DBV Investor Relations Contact
Katie Matthews+ 1 (857) 529-2363
katie.matthews@dbv-technologies.com
DBV Media Contact Angela
Marcucci+1 (646) 842-2393angela.marcucci@dbv-technologies.com
Viaskin and EPIT are trademarks of DBV
Technologies.
DBV Technologies (NASDAQ:DBVT)
Historical Stock Chart
From May 2024 to Jun 2024
DBV Technologies (NASDAQ:DBVT)
Historical Stock Chart
From Jun 2023 to Jun 2024